Current Report Filing (8-k)
November 09 2022 - 05:26PM
Edgar (US Regulatory)
false000149838200014983822022-11-092022-11-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 9, 2022
KINTARA THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
Nevada
|
001-37823
|
99-0360497
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
9920 Pacific Heights Blvd,
Suite 150
San Diego,
CA
92121
|
|
|
|
(Address of principal executive offices)
|
|
Registrant’s Telephone Number, Including Area Code:
(858)
350-4364
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4©)
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock
|
|
KTRA
|
|
The
Nasdaq Capital
Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
Kintara Therapeutics, Inc. (the “Company”) issued a press release
on November 9, 2022, disclosing financial information and operating
metrics for the first fiscal quarter ended September 30, 2022, and
providing a corporate update. A copy of the Company’s press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
See “Item 2.02 Results of Operation and Financial Condition”
above.
The information in this Current Report on Form 8-K under Items 2.02
and 7.01, including the information contained in Exhibit 99.1, is
being furnished to the Securities and Exchange Commission, and
shall not be deemed to be “filed” for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, and shall not be deemed
to be incorporated by reference into any filing under the
Securities Act of 1933, as amended, or the Securities Exchange Act
of 1934, as amended, except as shall be expressly set forth by a
specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
KINTARA THERAPEUTICS, INC.
|
|
|
|
|
|
Date: November 9, 2022
|
|
By:
|
|
/s/
Scott Praill
|
|
|
|
|
|
Name: Scott Praill
|
|
|
|
|
|
Title: Chief Financial Officer
|
2
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Mar 2023 to Apr 2023
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Apr 2022 to Apr 2023
